Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)‘s stock had its “outperform” rating reiterated by equities researchers at Oppenheimer Holdings, Inc. in a research report issued on Thursday. They presently have a $200.00 target price on the biopharmaceutical company’s stock. Oppenheimer Holdings, Inc.’s price objective would suggest a potential upside of 120.39% from the company’s current price.

Several other research firms also recently weighed in on ICPT. Wedbush reissued a “buy” rating on shares of Intercept Pharmaceuticals in a report on Monday, July 31st. Jefferies Group LLC reissued a “buy” rating and set a $275.00 price objective on shares of Intercept Pharmaceuticals in a report on Sunday, July 30th. Cantor Fitzgerald reissued an “underweight” rating and set a $69.00 price objective (up previously from $60.00) on shares of Intercept Pharmaceuticals in a report on Monday, July 31st. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Finally, Zacks Investment Research raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $136.00 price objective on the stock in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $205.48.

Shares of Intercept Pharmaceuticals (ICPT) traded down 2.39% during trading on Thursday, hitting $88.58. The stock had a trading volume of 1,586,890 shares. The stock has a 50 day moving average price of $111.73 and a 200-day moving average price of $116.97. The stock’s market capitalization is $2.22 billion. Intercept Pharmaceuticals has a one year low of $85.88 and a one year high of $172.95.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 135.24% and a negative net margin of 543.35%. The company had revenue of $30.89 million for the quarter, compared to the consensus estimate of $27.50 million. During the same quarter last year, the business posted ($3.14) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 459.6% on a year-over-year basis. On average, equities research analysts predict that Intercept Pharmaceuticals will post ($14.06) earnings per share for the current year.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/09/14/intercept-pharmaceuticals-inc-icpt-rating-reiterated-by-oppenheimer-holdings-inc.html.

In other news, insider Lisa Bright sold 394 shares of Intercept Pharmaceuticals stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $121.33, for a total value of $47,804.02. Following the completion of the transaction, the insider now directly owns 23,619 shares of the company’s stock, valued at approximately $2,865,693.27. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Daniel G. Welch sold 217 shares of Intercept Pharmaceuticals stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $126.76, for a total value of $27,506.92. Following the completion of the transaction, the director now directly owns 3,710 shares of the company’s stock, valued at $470,279.60. The disclosure for this sale can be found here. Over the last three months, insiders sold 48,013 shares of company stock valued at $6,198,747. Corporate insiders own 9.20% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. PNC Financial Services Group Inc. raised its position in shares of Intercept Pharmaceuticals by 0.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock worth $229,000 after acquiring an additional 14 shares in the last quarter. Public Employees Retirement Association of Colorado raised its position in shares of Intercept Pharmaceuticals by 1.1% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 43 shares in the last quarter. Janney Montgomery Scott LLC raised its position in shares of Intercept Pharmaceuticals by 1.8% in the 2nd quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock worth $416,000 after acquiring an additional 62 shares in the last quarter. WFG Advisors LP raised its position in shares of Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 125 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Intercept Pharmaceuticals by 14.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock worth $118,000 after acquiring an additional 132 shares in the last quarter. 82.19% of the stock is owned by hedge funds and other institutional investors.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.